AbbVie (WBO:ABBV) Other Long-Term Liabilities : €30,156 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is AbbVie Other Long-Term Liabilities?

AbbVie's other long-term liabilities for the quarter that ended in Mar. 2024 was €30,156 Mil.

AbbVie's quarterly other long-term liabilities declined from Sep. 2023 (€29,650 Mil) to Dec. 2023 (€28,234 Mil) but then increased from Dec. 2023 (€28,234 Mil) to Mar. 2024 (€30,156 Mil).

AbbVie's annual other long-term liabilities increased from Dec. 2021 (€22,610 Mil) to Dec. 2022 (€27,392 Mil) and increased from Dec. 2022 (€27,392 Mil) to Dec. 2023 (€28,234 Mil).

AbbVie Other Long-Term Liabilities Historical Data

The historical data trend for AbbVie's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Other Long-Term Liabilities Chart

AbbVie Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

AbbVie Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

AbbVie Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

AbbVie Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of AbbVie's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (WBO:ABBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ABBV:USA ABBV:Mexico 1ABBV:Italy 4ABd:UK 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.